Cerevance announced positive Phase 1 trial results for CVN293, a novel KCNK13 inhibitor targeting neuroinflammation. The drug was well-tolerated...

SELLAS Life Sciences announced positive Phase 2 trial data for SLS009 (tambiciclib), a CDK9 inhibitor, in relapsed/refractory acute myeloid...

Opus Genetics announced positive one-month data from the first pediatric patient in its Phase 1/2 trial of OPGx-LCA5, a...

Recursion Pharmaceuticals has dosed the first patient in a Phase 1 clinical trial, EXCELERIZE, for REC-3565, a potential best-in-class...

Real-world evidence (RWE) is increasingly referenced in regulatory conversations, particularly following the FDA’s 2023 guidance. Roche’s recent FDA clearance...

Multinational clinical trials are crucial for advancing medical innovation and improving patient outcomes. By including diverse populations, they provide...

NKGen Biotech announced updated Phase 1 clinical trial data for troculeucel, an NK cell therapy for moderate Alzheimer’s disease....

ALX Oncology received FDA clearance for its Investigational New Drug (IND) application for ALX2004, an antibody-drug conjugate (ADC) designed...

Teva Pharmaceuticals has submitted a supplemental Biologics License Application to the FDA for AJOVY (fremanezumab-vfrm) to prevent episodic migraines...

Reunion Neuroscience presented the design of its REKINDLE Phase 2 clinical trial, which will evaluate RE104 for treating adjustment...